Olive Oil

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: heart inflammation longevity

Research Overview

Human research on olive oil has most intensively examined cardiovascular-related outcomes, particularly lipid oxidation, blood lipids, blood pressure, and mechanistic biomarkers linked to atherosclerosis. A prominent feature across multiple randomized, crossover trials is the comparison of virgin/high-polyphenol olive oils versus refined/low-polyphenol oils while keeping fatty-acid composition broadly similar, allowing partial isolation of phenolic compounds’ effects. These studies commonly measure oxidized LDL and other oxidative stress markers (e.g., lipid peroxides, malondialdehyde, 8-oxo-dG), antioxidant enzyme activity (e.g., glutathione peroxidase), and lipid profiles (especially HDL cholesterol). Some trials also extend to molecular endpoints, reporting changes in expression of atherosclerosis- and inflammation-related genes in peripheral blood cells after high-polyphenol olive oil intake.

The strongest and most consistent evidence supports a dose-dependent antioxidant effect of olive oil phenolic compounds in vivo, particularly reductions in oxidized LDL and related oxidative damage markers, alongside increases in antioxidant defenses and modest improvements in HDL cholesterol. These effects are observed in healthy volunteers and in patients with coronary heart disease, and are reinforced by trials showing increased urinary/plasma phenolic metabolites (tyrosol/hydroxytyrosol) concurrent with improved oxidative endpoints. Evidence for blood-pressure lowering is more limited but suggests potential benefit in hypertensive subgroups consuming phenolic-rich virgin olive oil. In contrast, evidence for glycemic control benefits is weaker and inconsistent: a large meta-analysis of randomized trials reports no statistically significant overall effects on fasting glucose, insulin, HbA1c, or insulin resistance indices, indicating that any metabolic effects on glycemia may be small, context-dependent, or require different study designs/durations to detect.

Key gaps include the need for longer-duration trials with clinically meaningful cardiovascular endpoints (e.g., myocardial infarction, stroke) rather than predominantly short-term biomarker changes, as many interventions last days to weeks. More research is also needed to clarify heterogeneity by population (e.g., hypertensive vs normotensive, CHD vs healthy), background diet and antioxidant intake, and dose/form of olive oil (amount consumed, phenolic profile, and processing). Mechanistic findings on gene expression and inflammatory pathways are promising but require replication, standardized phenolic characterization, and linkage to hard outcomes. Finally, given the null overall findings for glycemic markers in meta-analysis, future studies should better define which subgroups (if any) benefit, and whether effects depend on replacing other fats, energy balance, or longer follow-up.

1. What conditions has Olive Oil been studied for?

  • Coronary heart disease (CHD) and cardiovascular risk: Studied in men with stable CHD, focusing on oxidized LDL, lipid peroxides, antioxidant enzymes, and blood pressure.

  • Hypertension (high blood pressure): Examined as an outcome within CHD patients, with subgroup findings in hypertensive participants.

  • Dyslipidemia / lipid profile modulation: Studied in healthy volunteers for HDL cholesterol, triglycerides, and cholesterol ratios.

  • Oxidative stress and LDL oxidation: Multiple trials assessed oxidized LDL, resistance of LDL to oxidation, lipid peroxidation markers, and postprandial oxidative stress.

  • Inflammation and atherosclerosis-related pathways: RCTs and a systematic review assessed inflammatory biomarkers (e.g., CRP, cytokines) and expression of pro-atherogenic genes in blood cells.

  • Glycemic control / insulin resistance and diabetes-related factors: A meta-analysis of 51 RCTs evaluated fasting glucose, insulin, HbA1c, and HOMA-IR.

2. Does it work in treating those conditions? Summarize the evidence.

  • CHD / cardiovascular risk markers: Likely beneficial for oxidative stress and LDL oxidation (short-term evidence).

    • In 40 men with stable CHD, virgin olive oil (high phenolics: 161 mg/kg) lowered plasma oxidized LDL (p<0.001) and lipid peroxide levels (p=0.003) and increased glutathione peroxidase activity (p=0.033) compared with refined oil (low phenolics: 14.7 mg/kg).

    • Across multiple crossover RCTs in healthy volunteers, higher-phenolic oils consistently produced dose-dependent reductions in oxidized LDL and improved LDL resistance to oxidation (e.g., oxidized LDL decreased with increasing phenolics; p=0.006 in one 30-person trial; and linear decreases in oxidized LDL in the 200-person multicenter trial).

    • Limitations: these are mostly short interventions (days to 3 weeks) and focus on biomarkers rather than clinical events (e.g., heart attacks).

  • Hypertension: Some evidence of systolic BP reduction in hypertensive individuals.

    • In the CHD crossover trial, systolic blood pressure decreased after virgin olive oil in hypertensive patients (p=0.001), while diastolic BP did not change.

    • Evidence base in these studies is limited to this subgroup finding; broader BP conclusions can’t be made from the provided data.

  • Lipids (HDL, triglycerides, ratios): Modest improvements, especially HDL, with higher phenolic content.

    • In the 200-person multicenter crossover RCT (25 mL/day for 3 weeks), HDL increased linearly with phenolic content (mean change: 0.025, 0.032, and 0.045 mmol/L for low/medium/high phenolics), and the total cholesterol:HDL ratio decreased linearly with phenolics.

    • In a 30-person crossover trial, HDL increased after virgin olive oil (p=0.029).

    • Triglycerides decreased slightly in the 200-person trial (average ~0.05 mmol/L across all oils), suggesting some effects may relate to olive oil generally (not only phenolics).

  • Inflammation / atherosclerosis-related gene expression: Early mechanistic evidence supports benefit with high-polyphenol oil.

    • In an 18-person crossover RCT (25 mL/day for 3 weeks), high-polyphenol olive oil (366 mg/kg) reduced systemic LDL oxidation and decreased expression of several proatherogenic/proinflammatory genes in peripheral blood mononuclear cells (including CD40L, IL23A, ADRB2, OLR1, IL8RA) compared with low-polyphenol oil (2.7 mg/kg).

    • A systematic review of 23 RCTs (1138 participants) reported EVOO was associated with reductions in ox-LDL (e.g., compared with low-PC oils: -7.73 U/L, 95% CI -14.63 to -0.82) and CRP compared with low-PC oils (-0.99 mg/L, 95% CI -1.66 to -0.31), but noted risk of bias and moderate to very low certainty with heterogeneity for CRP.

  • Glycemic control / diabetes outcomes: Overall neutral, with a possible dose range that improves insulin resistance (HOMA-IR).

    • A meta-analysis of 51 RCTs (n=4334) found no statistically significant overall changes in glucose, insulin, HbA1c, or HOMA-IR in primary analyses.

    • However, dose-response analyses suggested nonlinear relationships, and the authors concluded that 25–50 g/day may significantly improve HOMA-IR (insulin resistance marker), implying potential benefit in some contexts.

3. What health benefits does it have?

  • Reduced LDL oxidation and oxidative stress (most consistent finding across trials).

    • Multiple crossover RCTs show dose-dependent reductions in oxidized LDL with higher phenolic content oils (e.g., 200-person trial: oxidized LDL mean change improved progressively from low to high phenolics; 30-person trial: oxidized LDL decreased with phenolic content; CHD trial: oxidized LDL decreased after virgin oil).

    • Short-term studies also report improvements in oxidative damage markers (e.g., decreased urinary malondialdehyde and 8-oxo-dG, and increased glutathione peroxidase activity) in a phenolic dose-dependent manner.

    • Postprandial studies suggest phenolic-rich oils may blunt oxidation after a fat load, with phenolics absorbed (tyrosol/hydroxytyrosol) and incorporated into LDL.

  • Modest improvements in lipid profile, especially HDL cholesterol.

    • HDL increased in a phenolic dose-dependent fashion in the 200-person multicenter trial, and increased after virgin olive oil in a 30-person trial.

    • Total cholesterol:HDL ratio decreased linearly with phenolic content in the 200-person trial.

  • Potential blood pressure benefit (systolic) in hypertensive individuals.

    • In CHD patients who were hypertensive, systolic BP decreased after virgin olive oil (p=0.001), with no change in diastolic BP.

  • Anti-inflammatory and anti-atherogenic signaling effects (emerging evidence).

    • High-polyphenol olive oil reduced expression of several genes involved in atherogenic and inflammatory processes in vivo (18-person RCT), alongside reduced LDL oxidation.

    • Systematic review evidence suggests EVOO can reduce ox-LDL and may reduce CRP, though certainty varies and heterogeneity exists.

4. Does it have any downsides or side effects?

  • Caloric load / weight considerations (practical downside).

    • The trials used relatively large daily doses (commonly 25 mL/day, and up to 50 mL/day). Olive oil is energy-dense; increasing intake without reducing other calories could promote weight gain (not directly assessed in these studies, but relevant to real-world use).

  • Postprandial oxidative stress after a fat load (context-dependent).

    • One study noted that a 40 mL olive oil fat load promoted postprandial oxidative stress, but the degree of LDL oxidation was lower with higher phenolic content. This suggests phenolic-rich oils may mitigate, but not necessarily eliminate, oxidation associated with a large fat bolus.

  • Adverse events: not well characterized in the studies reviewed here.

    • The studies do not report major side effects; however, absence of reporting is not proof of absence. Gastrointestinal intolerance can occur with high oil intake in some people, but this is not addressed in the provided studies.

  • Evidence limitations that affect “downside” interpretation.

    • Many interventions were short (days to weeks), often in healthy men, and several outcomes are biomarkers. The systematic review noted risk of bias and moderate to very low certainty for inflammation/oxidative stress outcomes.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report analyses stratified by genotype, nor do they identify specific genetic variants that modify response (e.g., no APOE, FTO, PPARG, or antioxidant enzyme polymorphism subgroup results are described). Therefore:

  • No direct pharmacogenomic conclusions can be made from these studies.

  • Mechanistically, polyphenol-rich olive oil influenced gene expression related to atherosclerosis and inflammation (e.g., CD40L, OLR1, IL23A, IL8RA) in one RCT, but this reflects changes in expression after intake—not inherited genetic variation effects.

References

  1. Antioxidant effect of virgin olive oil in patients with stable coronary heart disease: a randomized, crossover, controlled, clinical trial
    M Fitó, M Cladellas, R de la Torre, J Martí, M Alcántara (2005)
  2. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial
    María-Isabel Covas, Kristiina Nyyssönen, Henrik E Poulsen, Jari Kaikkonen, Hans-Joachim F Zunft (2006)
  3. Olive oils high in phenolic compounds modulate oxidative/antioxidative status in men
    Tanja Weinbrenner, Montserrat Fitó, Rafael de la Torre, Guillermo T Saez, Philip Rijken (2004)
  4. Protection of LDL from oxidation by olive oil polyphenols is associated with a downregulation of CD40-ligand expression and its downstream products in vivo in humans
    Olga Castañer, María-Isabel Covas, Olha Khymenets, Kristiina Nyyssonen, Valentini Konstantinidou (2012)
  5. Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation--a randomized controlled trial
    Jaume Marrugat, María-Isabel Covas, Montserrat Fitó, Helmut Schröder, Elisabet Miró-Casas (2004)
  6. The Effect of Different Types of Olive Oil on Glucose Control and Insulin Sensitivity: A GRADE-Assessed Systematic Review and Dose-Response Meta-Analysis of 51 Randomized Controlled Trials
    Alireza Takhttavous, Kimia Rostampour, Shirin Gerami, Mohsen Mohammadi-Sartang (2025)
  7. Postprandial LDL phenolic content and LDL oxidation are modulated by olive oil phenolic compounds in humans
    María-Isabel Covas, Karina de la Torre, Magí Farré-Albaladejo, Jari Kaikkonen, Montserrat Fitó (2006)
  8. Changes in the phenolic content of low density lipoprotein after olive oil consumption in men. A randomized crossover controlled trial
    Eva Gimeno, Karina de la Torre-Carbot, Rosa M Lamuela-Raventós, Ana I Castellote, Montserrat Fitó (2007)
  9. Effects of daily extra virgin olive oil consumption on biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis
    Jéssica Vidal Damasceno, Anderson Garcez, Andressa Anelo Alves, Isabella Rosa da Mata, Simone Morelo Dal Bosco (2026)


Related

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!